A Yersinia pestis-derived fusion protein (F1-V) has shown great promise as a protective antigen against aerosol challenge with Y. pestis in murine studies. In the current study, we examined different prime-boost regimens with F1-V and demonstrate that (i) boosting by a route other than the route used for the priming dose (heterologous boosting) protects mice as well as homologous boosting against aerosol challenge with Y. pestis, (ii) parenteral immunization is not required to protect mice against aerosolized plague challenge, (iii) the route of immunization and choice of adjuvant influence the magnitude of the antibody response as well as the immunoglobulin G1 (IgG1)/IgG2a ratio, and (iv) inclusion of an appropriate adjuvant is critical for nonparenteral immunization.
Recently, a great deal of attention has been directed towards needle-free immunization strategies as alternative methods for vaccine delivery. Both mucosal (intranasal [i.n.], oral, and rectal) and transcutaneous (t.c.) immunization in the presence of an appropriate adjuvant have been shown to induce humoral and cellular immune responses in both the systemic and mucosal compartments of immunized animals. Alternating routes for delivery of the priming dose and booster dose in immunizations, so-called prime-boost strategies, have also been examined. Such prime-boost strategies could be particularly important in an imminent or postrelease bioterrorism event if it is possible to administer a parenteral priming dose and, at the same time, distribute a follow-up patch, pill, or nasal applicator that could be self administered. Such vaccine strategies would greatly improve national preparedness.
In a recent study, we evaluated different prime-boost regimens, including parenteral, mucosal, and transcutaneous delivery, in order to explore the effect of changing the route of prime and boost on the ability of the recombinant Yersinia pestis-derived fusion protein (F1-V) to promote the development of long-lasting, high-titer antibodies (13) . F1-V has been shown to provide protection against flea-borne, subcutaneous (s.c.), and aerosol challenge and has the potential to provide protective immunity against pneumonic as well as bubonic plague due to either wild-type F1 ϩ Y. pestis or to naturally occurring F1
Ϫ variants (16, 17) . The most significant finding of our previous study is that boosting by a different (heterologous) route than the priming dose can be as effective as or more effective than homologous boosting for induction of either serum or bronchoalveolar anti-F1-V immunoglobulin G1 (IgG1) responses.
In the current study, we examined the abilities of different prime-boost regimens with recombinant F1-V to protect mice against aerosol challenge with Y. pestis. We also examined the role of the coadministered adjuvant in inducing protection. For parenteral immunization, mice were immunized s.c. with 10 g of F1-V alone or adsorbed to alum adjuvant (2.0% Alhydrogel, batch no. 3275; Superfos Biosector, Vedbaek, Denmark) brought to a final volume of 100 l with 0.86 M NaCl. Mucosally and transcutaneously administered proteins are usually not immunogenic and also require the presence of an appropriate adjuvant. In the studies reported here, we utilized a mutant of the heat-labile enterotoxin of Escherichia coli, designated LT(R192G), that has been shown to be effective when administered mucosally (orally, rectally, or intranasally) or transcutaneously in a variety of animal models and in humans (2, 3, 5-7, 10, 12, 14, 19-24, 27-30, 32) . Mice immunized i.n. received 5 g of recombinant F1-V alone or admixed with 5 g LT(R192G), brought to a final volume of 9.6 l with TEAN (0.2 M NaCl, 0.05 M Tris, 0.001 M EDTA, 0.003 M NaN 3 , pH 7.5), in one nostril following brief exposure to Isofluorane. Mice immunized t.c. received 35 g F1-V alone or admixed with 25 g LT(R192G), brought to a final volume of 50 l with TEAN, applied to freshly shaved ventral skin following intraperitoneal injection of ketamine-xylazine. LT(R192G) was prepared in our laboratory by galactose-affinity chromatography as previously described (4) . The vaccine antigen was a non-His-tagged version of the F1-V fusion protein, expressed by T7 polymerase with lactose operator control in E. coli strain BLR(DE3)/pPW731 and isolated to 99% purity with a fourcolumn process (B.S. Powell, unpublished observation). Briefly, protein in clarified supernatant from disintegrated cells 
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was denatured with 6 M urea at room temperature. F1-V protein was then captured and refolded by anion exchange chromatography, further purified and concentrated over tandem hydrophobic interaction chromatography columns, and exchanged into phosphate-buffered saline by size exclusion chromatography before flash freezing and storage at Ϫ80°C.
Protein identity, quality, and structure were measured by several methods and determined to be as predicted. Bioburden in the form of nucleic acid and endotoxin ranged from 3 to 13 ng/mg and 25 to 379 endotoxin units/mg, respectively. Survival of immunized mice following aerosol challenge with Y. pestis. As shown in Table 1 , groups of 8-to 9-week-old female Swiss Webster mice were immunized twice (day 0 and day 28) with F1-V alone (s.c., i.n., or t.c) or adsorbed to alum (SCa) or admixed with LT(R192G) (INr or TCr), and groups of 10 animals from each regimen were challenged by aerosol with 70 50% lethal doses of Y. pestis (CO92) on day 87 following the primary immunizing dose of F1-V. The mice were challenged using a dynamic 30-liter humidity-controlled Plexiglas whole-body exposure chamber. Total flow through the chamber was 19.5 liters/minute and was maintained at atmospheric pressure throughout the exposure. The test atmosphere was continuously sampled by use of a 6-liter-per-minute all-glass impinger (Ace Glass, Vineland, NJ). Heart infusion broth with 0.001% (vol/wt) Antifoam A (Sigma, St. Louis, MO) was used as impingement collection medium. Nebulizer and all-glass impinger samples were plated after the exposure to establish the aerosol concentration within the exposure chamber. By use of the exposure concentration, an inhaled dose was estimated by multiplying the empirically determined aerosol exposure concentration (CFU/liter air) in the chamber by the amount of air that was estimated to have been breathed by the mouse during the exposure. The cumulative air breathed by each mouse during the exposures was calculated by estimating the respiratory minute volume based on Guyton's formula as previously described (15) . For this study, the average challenge dose over four runs of the aerosol system, expressed in total inhaled CFU/mouse was 1.5 ϫ 10 6 CFU. Survival was monitored for 216 h. Differences in survival between groups challenged with Y. pestis CO92 were analyzed by the Kaplan-Meier method with the log-rank Mantel-Haenszel test. Differences with P values of 0.05 or less were considered significant.
As seen in Fig. 1 and Table 2 , all animals in the naïve control group succumbed to infection following aerosol challenge with Y. pestis with a median survival time (MST) of 72 h. By contrast, 9/10 positive-control animals immunized with an SCa prime and an SCa boost (SCa ϫ SCa) with F1-V adsorbed to alum survived for the 216-h postchallenge observation period (P Ͻ 0.0001). Equivalent protection (9/10) was observed in animals primed INr and boosted INr in the presence of the adjuvant LT(R192G). Thus, homologous prime and boost with F1-V by either of the two routes in the presence of an appropriate adjuvant can provide significant protection against aerosol challenge. This is an important finding because it demonstrates that homologous mucosal immunization in the presence of an appropriate adjuvant can induce protection equivalent to parenteral immunization.
A primary objective of the experiments reported here was to determine if heterologous boosting could provide equivalent protection against aerosol challenge compared to homologous boosting. As shown in Fig. 1 and Table 2 , there were no differences in the survival rates of groups of animals primed INr and boosted SCa (10/10), primed SCa and boosted TCr (9/10), or primed TCr and boosted SCa (10/10) (heterologous prime-boost) compared to animals primed SCa and boosted SCa (9/10) or primed INr and boosted INr (9/10) (homologous prime-boost) if an appropriate adjuvant was included in the immunization. Differences in survival were observed if animals were immunized with F1-V without an adjuvant, depending upon the route of immunization. Thus, animals primed s.c. and boosted either s.c. or t.c. without adjuvant in either the priming or booster dose had equivalent protection (s.c. ϫ s.c. ϭ 7/10; s.c. ϫ t.c. ϭ 8/10) that was not significantly different from the levels of protection observed by any combination of routes that included adjuvant. By contrast, animals that were primed nonparenterally (e.g., i.n. or t.c.) with F1-V without adjuvant and then boosted i.n. or s.c. without adjuvant had significantly lower survival rates (i.n. ϫ i.n. ϭ 0/10; t.c. ϫ s.c. ϭ 4/10; i.n. ϫ s.c. ϭ 3/10) compared to animals primed and boosted with F1-V in the presence of the appropriate adjuvant. As shown in Fig. 1 and Table 2 Serum anti-F1-V IgG, IgG1, and IgG2a, as well as the serum anti-F1 and anti-V IgG responses in animals immunized with F1-V in the presence of an appropriate adjuvant, are shown in Table 3 and Fig. 2 . Consistent with our previous findings, heterologous boosting was as effective as, or more effective than, homologous boosting for induction of significant anti-F1-V responses in immunized animals. The highest concentration of serum anti-F1-V IgG was obtained by heterologous prime-boost [INr prime with F1-V admixed with LT(R192G) and SCa boost with F1-V adsorbed to alum], and that was also reflected in the concentrations of anti-F1-V IgG1 and IgG2a (Table 3) . With respect to serum anti-F1-V IgG1 and IgG2a Interestingly, there were no differences in protection against aerosol challenge between these immunization groups ( Fig. 1 and Table 2 ).
The most significant findings of the study reported here are that (i) heterologous boosting protects mice as well as homologous boosting against aerosol challenge with Y. pestis, (ii) parenteral immunization is not required to protect mice against aerosolized plague challenge (i.n. ϫ i.n. and s.c. ϫ s.c. provide equivalent protection if an appropriate adjuvant is included in the vaccine formulation), (iii) the route of immunization and choice of adjuvant influence the magnitude of the antibody response as well as the IgG1/IgG2a ratio, and (iv) inclusion of an appropriate adjuvant is more critical for nonparenteral immunization.
The finding that a vaccine delivered by heterologous primeboost can provide protection against aerosol challenge might have been predicted from our previous studies showing that the highest levels of anti-F1-V IgG1 were obtained by heterologous prime-boost. Related findings were reported by Eyles et al. (9), who demonstrated that t.c. application of F1 and V admixed with cholera toxin was effective for priming responses that could be boosted i.n. or intradermally and that t.c. application of F1 and V admixed with cholera toxin could effectively boost animals primed intradermally or i.n. However, the current study also demonstrates that i.n. priming in the context of an ADP-ribosylating adjuvant significantly lowers the serum IgG1/IgG2a ratio, indicating the development of more of a type 1 or mixed T-helper-cell response.
Moreover, INr ϫ INr homologous prime-boost and SCa ϫ TCr and TCr ϫ SCa heterologous prime-boost all induced significantly lower levels of IgG1 than either SCa ϫ SCa or INr ϫ SCa immunization. Importantly, all of these groups had identical levels of protection against aerosol challenge. There are two possible explanations for the observed equivalent protection in the face of vastly different amounts of IgG1. First, there may be a threshold level of anti-F1 or anti-V IgG1 that is sufficient for protection and any of the combinations of routes in the context of an appropriate adjuvant can achieve that level. In that case, achieving the higher levels of antibody Ϫ/Ϫ mice (inactivated IL-12 and interferon-␥-mediated immune mechanisms) were poorly protected, indicating that a type 1 immune mechanism, activated following Stat4 phosphorylation, may be essential for protection against plague. Thus, the undiminished protection following the observed shift to a type 1 or more mixed T-helper-cell response following i.n. priming in our study may reflect the contributions of both type 1 and type 2 responses to protection against aerosol challenge.
A number of studies have shown that the ADP-ribosylating enterotoxins can induce phenotypic and functional maturation of dendritic cells, as well as interacting directly with T-helper cells, B cells, and epithelial cells (1, 11, 18, 25, 26, 31) . We did not include antigen-only (nonadjuvant) controls in the cohort immunization study, but future studies comparing adjuvanted and nonadjuvanted immunization groups could resolve whether the IgG1/IgG2a ratio shift is a function of the route of immunization or adjuvant.
The discovery that immunization by one route can prime for a secondary response by another route and protect animals against high-dose lethal aerosol challenge has far-reaching implications, especially for national preparedness in a biodefense or emerging infectious disease crisis.
